LightTouch to be shown to international distributors, physicians and healthcare
purchasers
NORCROSS, Ga.--(Business Wire)--
Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP) today announced plans to
introduce its LightTouch non-invasive cancer detection technology at Medica 2009
in Düsseldorf, Germany November 18 - 20, 2009.
GT will be showcasing the LightTouch Cervical Neoplasia Detection System in
anticipation of a 2010 international launch. GT intends to meet with medical
device distributors with gynecological market expertise, as well as government
purchasing officials, in order to better understand the cervical cancer market
structure in the various countries.
The company is also looking to identify physicians who specialize in colposcopy
and cervical disease management in the interest of establishing partnerships for
multinational clinical studies involving the LightTouch.
"We believe the LightTouch will significantly improve the standard of care in
the area of cervical pre-cancer detection in a wide range of market settings,"
said Mark L. Faupel, Ph.D., President and CEO of GT. "Our experience in
launching new non-invasive detection technology indicates an international
product launch - while the technology is undergoing U.S. FDA premarket review -
permits us to have an earlier, positive affect on woman`s healthcare while
increasing shareholder value."
In conjunction with its partner Konica Minolta Opto, Inc. of Tokyo, GT will also
be holding design and feature requirement discussions with international
healthcare professionals for its LightTouch technology for detecting and
monitoring Barrett`s esophagus.
In cooperation with the Georgia Department of Economic Development, Guided
Therapeutics will be exhibiting in the North American Pavilion at Hall 16 D10-8.
Medica is the world`s largest medical industry tradeshow and more than 135,000
visitors from over 100 countries are expected to attend this annual event
About Guided Therapeutics
Guided Therapeutics, Inc. (Pink Sheets: GTHP) is developing a rapid and painless
test for the early detection of disease that leads to cervical cancer. The
technology is designed to provide an objective result at the point of care,
thereby improving the management of cervical disease. Unlike Pap and HPV tests,
the device does not require a painful tissue sample and results are known
immediately. GT also has an agreement with Konica Minolta Opto, Inc. (KMOT) of
Tokyo to co-develop non-invasive products, for the detection of lung and
esophageal cancer based on the company`s LightTouch non-invasive cervical cancer
detection technology. For more information, visit GT`s web site
www.guidedinc.com.
The Guided Therapeutics LightTouch Non-invasive Cervical Cancer Detection Device
is an investigational device and is limited by federal law to investigational
use.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995. A number of the matters and subject areas discussed in this news release
that are not historical or current facts deal with potential future
circumstances and developments. The discussion of such matters and subject areas
is qualified by the inherent risks and uncertainties surrounding future
expectations generally and also may materially differ from Guided Therapeutics`
actual future experience involving any of or more of such matters and subject
areas. Such risks and uncertainties include: the early stage of products in
development, the uncertainty of market acceptance of products, the uncertainty
of development or effectiveness of distribution channels, the intense
competition in the medical device industry, the uncertainty of capital to
develop products, the uncertainty of regulatory approval of products, dependence
on licensed intellectual property, as well as those that are more fully
described from time to time under the heading "Risk Factors" in Guided
Therapeutics` reports filed with the SEC, including Guided Therapeutics` Annual
Report on Form 10-KA for the fiscal year ended December 31, 2008 and subsequent
quarterly reports.
For Guided Therapeutics, Inc.
Bill Wells, 770-242-8723
Copyright Business Wire 2009
